AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24707184
Drug: Proactive multifactorial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive multifactorial intervention (PMI) using single-pill amlodipine/atorvastatin
Trial: 18728908
Drug: Multifaceted evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted evidence-based medicine intervention (didactic course + recurrent case-method learning sessions)
Trial: 12067856
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg testosterone enanthate (TE) weekly
Trial: 12067856
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg testosterone enanthate (TE) weekly
Trial: 12067856
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg testosterone enanthate (TE) weekly
Trial: 12067856
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg testosterone enanthate (TE) weekly
Trial: 12067856
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg testosterone enanthate (TE) weekly
Trial: 20562752
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sertraline per day
Trial: 19633103
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (subcutaneous administration, dosed to achieve Hb concentration of 13.0 g/dL, not exceeding 14.5 g/dL)
Trial: 19633103
Drug: Placebo (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous administration, sham adjustments of the dose)
Trial: 11774820
Drug: Thymopentin (TP-5)
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (TP-5) 1 mg/d for 20 days starting on 2 PBD
Trial: 8381187
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) - 400 mg/m2 cyclophosphamide, 40 mg/m2 doxorubicin, 60 mg/m2 cisplatin, administered in four courses at 3-week intervals starting 30 days post-surgery.
Trial: 8381187
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no adjuvant chemotherapy).
Trial: 3116821
Drug: NORPLANT‐2 implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NORPLANT‐2 implants
Trial: 3116821
Drug: NORPLANT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NORPLANT and NORPLANT‐2 implants
Trial: 1608407
Drug: Phenytoin treatment
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin treatment
Trial: 27792961
Drug: Cognitive-coping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-coping therapy (CCT)
Trial: 27792961
Drug: Pharmacotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy plus CCT (pCCT)
Trial: 26431718
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) 80 ppm for 3 days
Trial: 26431718
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) for patients with hypoxemia
Trial: 26431718
Drug: Inhaled nitrogen
RxNorm normalized name: nitrogen Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitrogen placebo for patients with hypoxemia
Trial: 11473953
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg three times a day for 3 months
Trial: 9608770
Drug: optimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: optimal treatment
Trial: 9608770
Drug: proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: proton pump inhibitors
Trial: 3191018
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (eutectic mixture of lignocaine and prilocaine)
Trial: 25935831
Drug: Tablet ranitidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet ranitidine, 150 mg; and tablet metoclopramide, 10 mg administered the night before and 2 hours before surgery
Trial: 24660591
Drug: Hypoglycemic anti-deafness
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemic anti-deafness capsules
Trial: 24660591
Drug: Glibenclamide and
RxNorm normalized name: Glibenclamide and metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide and conventional drug treatment for deafness
Trial: 17023848
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg IV dexamethasone
Trial: 17023848
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg IV dexamethasone
Trial: 30845873
Drug: β-Blockers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-Blockers
Trial: 14511896
Drug: Renin-angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system blockers in combination with diuretics, β-blockers, or calcium channel blockers
Trial: 11115810
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 800 mg/day for 12 weeks
Trial: 9314453
Drug: Meningococcal septic
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal septic shock treatment (specific intervention details not provided)
Trial: 8392077
Drug: Metoclopramide (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (7 mg/kg) plus dexamethasone (12 mg)
Trial: 3326678
Drug: Meclofenamate sodium
RxNorm normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclofenamate sodium 200 mg
Trial: 23973155
Drug: Ibuprofen (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (low and high dosages)
Trial: 23973155
Drug: Higher dosages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dosages of NSAIDs (Celecoxib, Diclofenac, Ibuprofen)
Trial: 15985582
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) at a target dose of 300 mg/day
Trial: 15985582
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) at a target dose of 300 mg/day
Trial: 15985582
Drug: Non-drug average
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug average
Trial: 14664266
Drug: Stabident intraosseous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabident intraosseous injection
Trial: 14664266
Drug: X-tip intraosseous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: X-tip intraosseous injection
Trial: 1512105
Drug: Ofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (300 mg orally, b.i.d.)
Trial: 1512105
Drug: Cephalexin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (500 mg orally, b.i.d.)
Trial: 6361791
Drug: Suprofen 200
RxNorm normalized name: suprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprofen 200 mg q.i.d.
Trial: 9625122
Drug: Aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 650 mg q.i.d.
Trial: 20589317
Drug: Edoxaban 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 90 mg once daily
Trial: 20589317
Drug: Dalteparin (control)
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (control) 2,500 IU initial, 5,000 IU subsequent doses once daily
Trial: 17521052
Drug: Preventive measures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive measures including fluid volume loading, discontinuation of nephrotoxic medications 48 hours prior to the study, minimizing CM volume and frequency, avoiding high-osmolar contrast in renal impairment, considering iso-osmolar contrast.
Trial: 11057351
Drug: Emedastine ophthalmic
RxNorm normalized name: emedastine ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emedastine ophthalmic solution 0.05% BID
Trial: 11057351
Drug: Levocabastine ophthalmic
RxNorm normalized name: levocabastine ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine ophthalmic suspension 0.05% BID
Trial: 9376749
Drug: Gidazepam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gidazepam (20 mg test dose, 40 mg daily, 14-day course)
Trial: 9376749
Drug: Phenazepam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenazepam (0.5 mg and 1 mg test doses, daily dose 2 mg, 14-day course)
Trial: 8251874
Drug: Extended cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended cognitive behavioral treatment (CB)
Trial: 7018164
Drug: Tinidazole 2
RxNorm normalized name: tinidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 2 g single oral dose
Trial: 23538338
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine plus daunorubicin and etoposide
Trial: 23538338
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine plus daunorubicin and etoposide
Trial: 20659966
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment without reduction
Trial: 17590313
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality (VR) activity, 2-3 times weekly for 12 weeks using GestureTek's Gesture Xtreme video capture VR system
Trial: 16836708
Drug: Cocaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (20 mg)
Trial: 31593637
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplement at a dose of 50,000 IU/week (n = 23)
Trial: 31593637
Drug: CrPic supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CrPic supplement at a dose of 500 μg/day (n = 23)
Trial: 31593637
Drug: Both vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vitamin D3 at a dose of 50,000 IU/week and CrPic at a dose of 500 μg/day (n = 23)
Trial: 29747625
Drug: Leaflet cluster
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leaflet cluster (oral health education through leaflets)
Trial: 29747625
Drug: E-learning cluster
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-learning cluster (oral health education through E-learning program)
Trial: 27025586
Drug: Endocrine Treatment
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine Treatment (ET) + Radiotherapy (RAD)
Trial: 22418829
Drug: ACT‐077825 (1-1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT‐077825 (1-1,000 mg)
Trial: 18715218
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of CrPic for 8 weeks
Trial: 18715218
Drug: Intraperitoneal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal administration of CrPic (0, 1, 10, or 50 microg/kg)
Trial: 18715218
Drug: Intracerebroventricular administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracerebroventricular administration of CrPic (0, 0.4, 4, or 40 ng)
Trial: 16439811
Drug: Petrolatum-based ointments
RxNorm normalized name: PETROLATUM BASE
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petrolatum-based ointments
Trial: 10376614
Drug: Metoprolol CR/XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/XL 12.5 mg (NYHA III‐IV) or 25.0 mg once daily (NYHA II), target dose 200 mg once daily, up-titrated over 8 weeks
Trial: 29211888
Drug: OCP +
RxNorm normalized name: Oral Contraceptive Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCP + BC (50 mg/d)
Trial: 24469526
Drug: Psychodynamic psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic psychotherapy plus adjunctive pharmacotherapy
Trial: 22386831
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg daily
Trial: 14502372
Drug: Erythromycin estolate,
RxNorm normalized name: Erythromycin Estolate, estolate 250 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin estolate, 20 mg kg‐1 day‐1, divided into four oral doses for 4 weeks
Trial: 10732392
Drug: Saw palmetto
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saw palmetto extract (SPE) 160 mg standardized extract twice daily
Trial: 1327632
Drug: Liquorice (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquorice (7 days of oral administration)
Trial: 1327632
Drug: Cortisol (intra-arterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (intra-arterial infusion)
Trial: 3901992
Drug: Cephamandole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephamandole (1 g single dose given 1 hour before surgery)
Trial: 3901992
Drug: Cephamandole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephamandole (1 g single dose)
Trial: 20493567
Drug: Captopril or
RxNorm normalized name: captopril Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril or Losartan (not specified dosage or duration)
Trial: 16719233
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 to 8 mg daily)
Trial: 16719233
Drug: Glibenclamide (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (3.5 to 10.5 mg daily)
Trial: 11413528
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy (various protocols including intraarterial and intravenous epirubicin, oral tegafur, carmofur)
Trial: 802975
Drug: Anesthetic (sensory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetic (sensory deprivation of the oral cavity via nerve-block injections)
Trial: 21467538
Drug: Visionary leaders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visionary leaders (those who offer novel solutions)
Trial: 16575425
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo treatment over the left OFC
Trial: 2965135
Drug: Teicoplanin 400
RxNorm normalized name: Teicoplanin 400 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 400 mg daily
Trial: 2965135
Drug: Vancomycin 1
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1 g bd
Trial: 24815417
Drug: Diclofenac 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 0.1 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Trial: 24815417
Drug: Diclofenac 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 0.5 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Trial: 24815417
Drug: Diclofenac 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 2.0 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Trial: 24815417
Drug: Diclofenac 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 0.1 mg·kg(‐1) only
Trial: 24815417
Drug: Diclofenac 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 0.5 mg·kg(‐1) only
Trial: 24815417
Drug: Diclofenac 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 2.0 mg·kg(‐1) only
Trial: 24815417
Drug: Acetaminophen 30
RxNorm normalized name: acetaminophen 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 30 mg·kg(‐1)
Trial: 22791166
Drug: Risedronate (17.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (17.5 mg weekly)
Trial: 16128676
Drug: Probiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic mixture containing Lactobacillus rhamnosus GG, L. rhamnosus LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp. shermanii JS, taken daily for 6 months.
Trial: 16128676
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule taken daily for 6 months.
Trial: 10086942
Drug: Ventstream nebuliser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventstream nebuliser (MMD, 3.3 microm; delivery rate, 0.075 ml/min)
Trial: 10086942
Drug: Optimist nebuliser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimist nebuliser (MMD, 1.8 microm; delivery rate, 0.02 ml/min)
Trial: 7822046
Drug: Live oral
RxNorm normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live oral cholera vaccine CVD 103-HgR
Trial: 2239116
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg 0.5% bupivacaine after free drops of CSF (Group I)
Trial: 2239116
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg 0.5% bupivacaine after removal of 3 ml CSF (Group II)
Trial: 2239116
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg 0.5% bupivacaine after removal of 5 ml CSF (Group III)
Trial: 497087
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide administration
Trial: 497087
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide administration
Trial: 497087
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous and oral cyclophosphamide administration
Trial: 23378064
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of Fulvestrant 500 mg to Fulvestrant 250 mg
Trial: 21098066
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (education session with monthly phone follow-ups)
Trial: 1767056
Drug: Iopamidol 150
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iopamidol 150 mgI/ml (250 ml)
Trial: 1767056
Drug: Iopamidol 370
RxNorm normalized name: iopamidol 370 mg iodine/mL (76 %) INTRAVEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol 370 mgI/ml (100 ml)
Trial: 6120311
Drug: Slow-release aminophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release aminophylline (mean 683 mg; 10.4 mg/kg)
Trial: 31980342
Drug: Control for
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control for neurocognition, antipsychotic medication, and depressive symptoms
Trial: 28688269
Drug: Horticulture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horticulture therapy in specially designed urban green environments
Trial: 28688269
Drug: Occupational art
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Occupational art therapy (control group)
Trial: 25577543
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg) with budesonide (400 µg)
Trial: 25577543
Drug: Doxofylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxofylline (400 mg) with budesonide (400 µg)
Trial: 25577543
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 µg) with budesonide (400 µg)
Trial: 25577543
Drug: Formoterol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (12 µg) with budesonide (400 µg)
Trial: 17215602
Drug: Programmed Information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed Information for Parental Coping before Intravenous Procedure (PIPC‐IP)
Trial: 14653130
Drug: Ginkgo Biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo Biloba capsule
Trial: 11015996
Drug: Oral 5'-DFUR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5'-DFUR (610 mg/m2/day x 10 days or over) preoperatively
Trial: 11015996
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment preoperatively (Group II)
Trial: 11015996
Drug: Oral 5'-DFUR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5'-DFUR (good compliance)
Trial: 11015996
Drug: Oral 5'-DFUR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5'-DFUR (poor compliance)